Trial Profile
Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms DIRECT registry
- 01 Mar 2022 Results assessing sex difference in patient characteristics and clinical outcomes of the NVAF patients treated with DOAC in the real-world Japanese trial published in the Heart and Vessels
- 18 Nov 2019 Results assessing impact of renal function on bleeding risk presented at the American Heart Association Scientific Sessions 2019.
- 25 Jan 2019 Results published in the American Journal of Cardiology.